Aditxt, Inc. (ADTX) is a pre-commercial-stage biopharmaceutical company with a balance sheet that yields deeply negative liquidation recovery to equity under any defensible asset haircut schedule. As of December 31, 2025, total reported assets are $16.5M against total liabilities of $12.6M, producing GAAP book equity (attributable to the parent) of $5.6M and total equity including NCI of $3.95M. However, the MFFAIS liquidation estimates correctly flag negative equity recovery: cash of $3.2M recovers at par, but the next largest asset block—investments of $6.6M—consists of Evofem convertible notes carried at fair value and subject to a $23.8M unrealized gain recognized in the period. Under liquidation, that Level 3 asset would be heavily discounted or worthless given Evofem's distressed status; the filing discloses a $4.75M deferred tax asset specifically for the Evofem investment loss, signaling the tax basis diverges materially from book carrying value. PP&E gross of $3.0M carries $2.1M accumulated depreciation, leaving net book value of $0.88M; at 50-60% haircut, recoverable value is approximately $0.4-0.5M. Intangibles net to $2,778—effectively zero under liquidation. The ROU asset of $1.2M is offset by $1.15M in operating lease liability, which does not extinguish on wind-up. Liability stack includes $12.2M current liabilities (accounts payable and accrued liabilities of $7.7M, notes payable current of $1.9M, operating lease current of $0.8M, deferred rent current of $0.05M) plus $0.34M noncurrent operating lease and $2 in noncurrent derivative liability. Critically, the company carries $7.0M in fair value liabilities (tagged as FairValueHedgeLiabilitiesAtFairValue and LiabilitiesFairValueDisclosure) representing Series A-1 convertible preferred stock reclassified to mandatorily redeemable liability status—these remain at face value in liquidation and consume recoverable assets ahead of common equity. The accumulated deficit is ($209.8M); the company lost $42.8M pre-tax in 2025 versus $35.0M in 2024, a 22% acceleration in cash consumption. Operating cash outflow was ($25.7M) for 2025, funded by $30.5M in financing activities including ATM equity issuance and new debt issuances. Post-period events include a Nasdaq minimum equity deficiency notice (extension to May 15, 2026 conditioned on completing financing), a $36M preferred stock acquisition of Ignite Proteomics (financial impact undetermined as of filing), a $3.2M OID promissory note issuance in March 2026, and a 1-for-8 reverse stock split effective March 2026. The Vertalo lawsuit ($0.8M+ exposure) adds contingent liability. The deferred tax asset of $44.8M (gross) is fully reserved by a $44.5M valuation allowance, confirming management does not expect realization. Net federal NOL carryforwards total $99.9M post-2017 (indefinite carryforward) but are subject to Section 382 limitations from repeated equity raises and restructurings. Filing discusses Evofem investment impairment and fair value of the convertible notes in MD&A but does not separately tag those impairment amounts in XBRL—only the aggregate AssetImpairmentCharges of $412K is tagged. The overall liquidation posture is materially negative to equity; common shareholders would receive zero recovery.
▼ Community Notes